| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5695549 | Gynecologic Oncology | 2017 | 6 Pages |
Abstract
Genotyping and targeted sequencing of Type I EOCs frequently identifies actionable mutations. Matched treatment with MEK-based combination therapy in KRAS and/or NRAS mutant type I EOC patients is an active therapeutic strategy.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
A. Spreafico, A.M. Oza, B.A. Clarke, H.J. Mackay, P. Shaw, M. Butler, N.C. Dhani, S. Lheureux, M.K. Wilson, S. Welch, T. Zhang, C. Yu, T. Stockley, L.L. Siu, S. Kamel-Reid, P.L. Bedard,